Megan Stafford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Megan Stafford has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Andrew Lloyd
United Biosource Corporation, London, UK
1 shared publication- Beenish Nafees
Icon PLC, Oxford, UK
1 shared publication - Jessamy Watkins
Eli Lilly, UK, Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL, UK
1 shared publication - Shkun Bhalla
Former employee of Eli Lilly, UK, Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL, UK
1 shared publication Sonia Gavriel
United Biosource Corporation, London, UK
1 shared publication- Sonia Gavriel
United BioSource Corporation, UK, 20 Bloomsbury Square, London, WC1A 2NS, UK
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 1 January 2008
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 6 (1) , 84
Health state utilities for non small cell lung cancer
Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash and hair loss.
- 1 January 2008
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 6 (1) , 84
Top Cited PapersOpen AccessHealth state utilities for non small cell lung cancer
Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash and hair loss.
- 1 August 2007
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 7 (4) , 373-384
Patient-reported outcomes measurements in epilepsy
This review was designed to explore and review the range of patient-reported outcomes used to assess people with epilepsy. Literature searches were conducted through EMBASE.com and supplemented with hand searching of relevant articles. References obtained through hand searches were compared with EMBASE.com citations until we were confident that the review had reached a point of saturation. The search included English language papers published between January 1997 and March 2007. Searching through EMBASE.com yielded a total of 110 hits and the hand searches identified 35 potentially relevant studies. A total of 61 studies were considered relevant to the current review and were included in the study. Several instruments that have been designed and validated to measure patient-reported outcomes in an epilepsy population are currently being used, including the Quality of Life in Epilepsy (QOLIE)-89 and -31, the Liverpool Seizure Severity Scale and the Washington Psychosocial Seizure Inventory. In addition, the QOLIE-adolescent (QOLIE-AD)-48 and the Adolescent Psychosocial Seizure Inventory have been designed for use with adolescent epileptic patients. We found a paucity of valid condition-specific instruments assessing patient preference and patient satisfaction in this population. Several condition-specific instruments exist to measure patient-reported outcomes in epilepsy, specifically in the areas of health-related quality of life, patient-reported symptoms and psychosocial functioning. However, measures designed to assess other areas of patient-reported outcomes, such as patient preference and satisfaction, are poorly developed.
- 1 August 2007
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 7 (4) , 373-384
Patient-reported outcomes measurements in epilepsy
This review was designed to explore and review the range of patient-reported outcomes used to assess people with epilepsy. Literature searches were conducted through EMBASE.com and supplemented with hand searching of relevant articles. References obtained through hand searches were compared with EMBASE.com citations until we were confident that the review had reached a point of saturation. The search included English language papers published between January 1997 and March 2007. Searching through EMBASE.com yielded a total of 110 hits and the hand searches identified 35 potentially relevant studies. A total of 61 studies were considered relevant to the current review and were included in the study. Several instruments that have been designed and validated to measure patient-reported outcomes in an epilepsy population are currently being used, including the Quality of Life in Epilepsy (QOLIE)-89 and -31, the Liverpool Seizure Severity Scale and the Washington Psychosocial Seizure Inventory. In addition, the QOLIE-adolescent (QOLIE-AD)-48 and the Adolescent Psychosocial Seizure Inventory have been designed for use with adolescent epileptic patients. We found a paucity of valid condition-specific instruments assessing patient preference and patient satisfaction in this population. Several condition-specific instruments exist to measure patient-reported outcomes in epilepsy, specifically in the areas of health-related quality of life, patient-reported symptoms and psychosocial functioning. However, measures designed to assess other areas of patient-reported outcomes, such as patient preference and satisfaction, are poorly developed.